Myovant Sciences (MYOV) Stock Price, News & Analysis

Company Overview

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $26.98 to $27.00
• 50-Day Range: $26.88 to $26.99
• 52-Week Range: $7.67 to $27.06
• Volume: 2.26 million shs
• Average Volume: 1.17 million shs
• Market Capitalization: $2.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MYOV Stock Analysis - Frequently Asked Questions

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) issued its quarterly earnings data on Tuesday, October, 26th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.11. The business earned $77.90 million during the quarter, compared to analyst estimates of $72.67 million.

When did Myovant Sciences IPO?

Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 10/26/2021
• Today: 11/24/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:MYOV
• Previous Symbol: NASDAQ:MYOV
• CUSIP: N/A
• CIK: 1679082
• Web: www.myovant.com
• Phone: 442074003351
• Fax: N/A
• Employees: 407
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-205,980,000.00
• Net Margins: -48.47%
• Pretax Margin: -42.81%
• Return on Equity: N/A
• Return on Assets: -39.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.57
• Quick Ratio: 1.45

Sales & Book Value

• Annual Sales: $230.97 million
• Price / Sales: 11.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.04) per share
• Price / Book: -5.35

Miscellaneous

• Outstanding Shares: 97,240,000
• Free Float: 95,388,000
• Market Cap: $2.62 billion
• Optionable: Not Optionable
• Beta: 2.17